Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level

Viviane D. Lima, David Bangsberg, P. Richard Harrigan, Steven G. Deeks, Benita Yip, Robert S. Hogg, Julio S G Montaner

Research output: Contribution to journalArticle

98 Citations (Scopus)

Abstract

Objective: To model the effect of adherence and duration of viral suppression on the risk of viral rebound. Methods: Viral rebound was defined as the first of at least two consecutive viral loads greater than 400 copies/mL after initial viral suppression. The main exposures were adherence, presence of antiretroviral class resistance before rebound or censoring date, and the percentage of follow-up time with viral suppression. Results: A total of 274 (N = 1305 [21%]) individuals experienced viral rebound. Median time of suppression before rebound was 2 years. Viral rebound was less likely to occur among those with longer duration of continuous viral suppression (odds ratio, 0.37; 95% confidence interval, 0.32 to 0.42). Among individuals with moderate levels of adherence (80% to less than 95%), the probability of virologic failure was 0.85 after being suppressed for 12 months and it was 0.08 after 72 months being suppressed (P < 0.01). Individuals with drug resistance were at a higher risk of viral rebound. Conclusions: The risk of viral rebound decreased with longer duration of viral suppression within each of adherence strata studied. Although perfect adherence remains an important goal of therapy to prevent disease progression, individuals with long-term viral suppression may be able to miss more doses without experiencing viral rebound.

Original languageEnglish (US)
Pages (from-to)460-465
Number of pages6
JournalJournal of Acquired Immune Deficiency Syndromes
Volume55
Issue number4
DOIs
StatePublished - Dec 1 2010
Externally publishedYes

Fingerprint

Highly Active Antiretroviral Therapy
Viral Load
Drug Resistance
Disease Progression
Odds Ratio
Confidence Intervals
Therapeutics

Keywords

  • adherence
  • HAART
  • long-term suppression
  • resistance
  • viral rebound
  • virologic failure

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level. / Lima, Viviane D.; Bangsberg, David; Harrigan, P. Richard; Deeks, Steven G.; Yip, Benita; Hogg, Robert S.; Montaner, Julio S G.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 55, No. 4, 01.12.2010, p. 460-465.

Research output: Contribution to journalArticle

Lima, Viviane D. ; Bangsberg, David ; Harrigan, P. Richard ; Deeks, Steven G. ; Yip, Benita ; Hogg, Robert S. ; Montaner, Julio S G. / Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level. In: Journal of Acquired Immune Deficiency Syndromes. 2010 ; Vol. 55, No. 4. pp. 460-465.
@article{c605a787eb1449adaed8df28e2c91dc7,
title = "Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level",
abstract = "Objective: To model the effect of adherence and duration of viral suppression on the risk of viral rebound. Methods: Viral rebound was defined as the first of at least two consecutive viral loads greater than 400 copies/mL after initial viral suppression. The main exposures were adherence, presence of antiretroviral class resistance before rebound or censoring date, and the percentage of follow-up time with viral suppression. Results: A total of 274 (N = 1305 [21{\%}]) individuals experienced viral rebound. Median time of suppression before rebound was 2 years. Viral rebound was less likely to occur among those with longer duration of continuous viral suppression (odds ratio, 0.37; 95{\%} confidence interval, 0.32 to 0.42). Among individuals with moderate levels of adherence (80{\%} to less than 95{\%}), the probability of virologic failure was 0.85 after being suppressed for 12 months and it was 0.08 after 72 months being suppressed (P < 0.01). Individuals with drug resistance were at a higher risk of viral rebound. Conclusions: The risk of viral rebound decreased with longer duration of viral suppression within each of adherence strata studied. Although perfect adherence remains an important goal of therapy to prevent disease progression, individuals with long-term viral suppression may be able to miss more doses without experiencing viral rebound.",
keywords = "adherence, HAART, long-term suppression, resistance, viral rebound, virologic failure",
author = "Lima, {Viviane D.} and David Bangsberg and Harrigan, {P. Richard} and Deeks, {Steven G.} and Benita Yip and Hogg, {Robert S.} and Montaner, {Julio S G}",
year = "2010",
month = "12",
day = "1",
doi = "10.1097/QAI.0b013e3181f2ac87",
language = "English (US)",
volume = "55",
pages = "460--465",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level

AU - Lima, Viviane D.

AU - Bangsberg, David

AU - Harrigan, P. Richard

AU - Deeks, Steven G.

AU - Yip, Benita

AU - Hogg, Robert S.

AU - Montaner, Julio S G

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Objective: To model the effect of adherence and duration of viral suppression on the risk of viral rebound. Methods: Viral rebound was defined as the first of at least two consecutive viral loads greater than 400 copies/mL after initial viral suppression. The main exposures were adherence, presence of antiretroviral class resistance before rebound or censoring date, and the percentage of follow-up time with viral suppression. Results: A total of 274 (N = 1305 [21%]) individuals experienced viral rebound. Median time of suppression before rebound was 2 years. Viral rebound was less likely to occur among those with longer duration of continuous viral suppression (odds ratio, 0.37; 95% confidence interval, 0.32 to 0.42). Among individuals with moderate levels of adherence (80% to less than 95%), the probability of virologic failure was 0.85 after being suppressed for 12 months and it was 0.08 after 72 months being suppressed (P < 0.01). Individuals with drug resistance were at a higher risk of viral rebound. Conclusions: The risk of viral rebound decreased with longer duration of viral suppression within each of adherence strata studied. Although perfect adherence remains an important goal of therapy to prevent disease progression, individuals with long-term viral suppression may be able to miss more doses without experiencing viral rebound.

AB - Objective: To model the effect of adherence and duration of viral suppression on the risk of viral rebound. Methods: Viral rebound was defined as the first of at least two consecutive viral loads greater than 400 copies/mL after initial viral suppression. The main exposures were adherence, presence of antiretroviral class resistance before rebound or censoring date, and the percentage of follow-up time with viral suppression. Results: A total of 274 (N = 1305 [21%]) individuals experienced viral rebound. Median time of suppression before rebound was 2 years. Viral rebound was less likely to occur among those with longer duration of continuous viral suppression (odds ratio, 0.37; 95% confidence interval, 0.32 to 0.42). Among individuals with moderate levels of adherence (80% to less than 95%), the probability of virologic failure was 0.85 after being suppressed for 12 months and it was 0.08 after 72 months being suppressed (P < 0.01). Individuals with drug resistance were at a higher risk of viral rebound. Conclusions: The risk of viral rebound decreased with longer duration of viral suppression within each of adherence strata studied. Although perfect adherence remains an important goal of therapy to prevent disease progression, individuals with long-term viral suppression may be able to miss more doses without experiencing viral rebound.

KW - adherence

KW - HAART

KW - long-term suppression

KW - resistance

KW - viral rebound

KW - virologic failure

UR - http://www.scopus.com/inward/record.url?scp=78650230394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650230394&partnerID=8YFLogxK

U2 - 10.1097/QAI.0b013e3181f2ac87

DO - 10.1097/QAI.0b013e3181f2ac87

M3 - Article

VL - 55

SP - 460

EP - 465

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 4

ER -